Want to see OBX full AI Analyst Report?
Total Valuation
Obsidian Therapeutics has a market cap or net worth of $1.05B. The enterprise value is $148.50.
Market Cap$1.05B
Enterprise Value$148.50
Share Statistics
Obsidian Therapeutics has 61,772,877 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61,772,877
Owned by Insiders98.80%
Owned by Institutions―
Financial Efficiency
Obsidian Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count87
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Obsidian Therapeutics is <0.1. Obsidian Therapeutics’s PEG ratio is -0.00003.
PE Ratio<0.1
PS Ratio0.00
PB Ratio0.33
Price to Fair Value―
Price to FCF-0.36
Price to Operating Cash Flow―
PEG Ratio-0.00003
Income Statement
In the last 12 months, Obsidian Therapeutics had revenue of ― and earned ― in profits. Earnings per share was ―.
Revenue―
Gross Profit―
Operating Income―
Pretax Income―
Net Income―
EBITDA―
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Obsidian Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.65
52-Week Price Change272.50%
50-Day Moving Average19.31
200-Day Moving Average13.48
Relative Strength Index (RSI)38.49
Average Volume (3m)476.74K
Important Dates
Obsidian Therapeutics upcoming earnings date is Aug 18, 2025, Before Open (Confirmed).
Last Earnings DateMay 19, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
Obsidian Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Obsidian Therapeutics has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
Obsidian Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Obsidian Therapeutics has ― in cash and marketable securities with $0.00 in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt$0.00
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Obsidian Therapeutics is $40.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$40.00
Price Target Upside110.53% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast―